Skip to main content
Top
Published in: Archives of Virology 7/2017

01-07-2017 | Original Article

High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients

Authors: Sandrine Castelain, Véronique Descamps, Etienne Brochot, François Helle, Gilles Duverlie, Eric Nguyen-Khac, Catherine François

Published in: Archives of Virology | Issue 7/2017

Login to get access

Abstract

The progression of liver disease in hepatitis B virus (HBV) infection is fostered by active virus replication. Mutations in the basal core promoter (BCP) and precore (PC) regions of the HBV genome are known to have an impact on viral replication. The aim of the present study was to assess the correlation of mutation profiles in the BCP and PC regions with the viral load in HBeAg-negative chronically infected patients. The HBV genotype, BCP/PC mutations, serum HBV DNA levels, and associated serological markers were analyzed in 92 HBeAg-negative chronically infected patients. Sequence analysis of the BCP and PC regions revealed variability of 19% and 24.1%, respectively. This variability was primarily associated with five critical positions (1753, 1762, 1764, 1896 and 1899). An elevated HBV viral load (>20,000 IU/ml) was classically correlated with F2-F4 liver fibrosis, elevated serum alanine aminotransferase levels, 1762/1764 and 1753 combination mutations, and surprisingly, with an 1858T-1896G double mutation that impairs base pairing at the base of the bulge in the ε encapsidation signal. An analysis of covariance confirmed the independent nature of the relationship between the 1858T-1896G double mutation and the HBV viral load. In conclusion, independently of conventional parameters, this study demonstrates that a high serum HBV DNA level was also associated with PC 1858-1896 mutations. These BCP/PC mutations may have important clinical implications as predictive factors for HBV DNA increase.
Literature
3.
go back to reference Hatzakis A, Wait S, Bruix J et al (2011) The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 18(Suppl 1):1–16CrossRefPubMed Hatzakis A, Wait S, Bruix J et al (2011) The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 18(Suppl 1):1–16CrossRefPubMed
4.
go back to reference Iloeje UH, Yang HI, Su J et al (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678–686CrossRefPubMed Iloeje UH, Yang HI, Su J et al (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678–686CrossRefPubMed
5.
go back to reference Chen CJ, Yang HI, Iloeje UH (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49:S72–S84CrossRefPubMed Chen CJ, Yang HI, Iloeje UH (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49:S72–S84CrossRefPubMed
6.
go back to reference Chen CF, Lee WC, Yang HI et al (2011) Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 141:1240–1248 (1248 e1241–1242) CrossRefPubMed Chen CF, Lee WC, Yang HI et al (2011) Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 141:1240–1248 (1248 e1241–1242) CrossRefPubMed
7.
go back to reference Kurbanov F, Tanaka Y, Mizokami M (2010) Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 40:14–30CrossRefPubMed Kurbanov F, Tanaka Y, Mizokami M (2010) Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 40:14–30CrossRefPubMed
9.
go back to reference Harrison TJ (2006) Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 26:87–96CrossRefPubMed Harrison TJ (2006) Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 26:87–96CrossRefPubMed
10.
go back to reference Hunt CM, McGill JM, Allen MI et al (2000) Clinical relevance of hepatitis B viral mutations. Hepatology 31:1037–1044CrossRefPubMed Hunt CM, McGill JM, Allen MI et al (2000) Clinical relevance of hepatitis B viral mutations. Hepatology 31:1037–1044CrossRefPubMed
11.
go back to reference Lindh M, Furuta Y, Vahlne A et al (1995) Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotides 1858 of 1896. J Infect Dis 172:1343–1347CrossRefPubMed Lindh M, Furuta Y, Vahlne A et al (1995) Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotides 1858 of 1896. J Infect Dis 172:1343–1347CrossRefPubMed
12.
go back to reference Lindh M, Horal P, Dhillon AP et al (1996) Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 24:494–501CrossRefPubMed Lindh M, Horal P, Dhillon AP et al (1996) Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 24:494–501CrossRefPubMed
13.
14.
go back to reference Croagh CMN, Desmond PV, Bell SJ (2015) Genotypes and viral variants in chronic hepatitis B: a review of epidemiology and clinical relevance. World J Hepatol 27:289–303CrossRef Croagh CMN, Desmond PV, Bell SJ (2015) Genotypes and viral variants in chronic hepatitis B: a review of epidemiology and clinical relevance. World J Hepatol 27:289–303CrossRef
15.
go back to reference Ahn SH, Kramvis A, Kawai S et al (2003) Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology 125:1370–1378CrossRefPubMed Ahn SH, Kramvis A, Kawai S et al (2003) Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology 125:1370–1378CrossRefPubMed
16.
go back to reference Kozak M (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 196:947–950CrossRefPubMed Kozak M (1987) At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 196:947–950CrossRefPubMed
17.
18.
go back to reference Yu X, Mertz JE (1996) Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 70:8719–8726PubMedPubMedCentral Yu X, Mertz JE (1996) Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 70:8719–8726PubMedPubMedCentral
19.
go back to reference Yu X, Mertz JE (1997) Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily. J Virol 71:9366–9374PubMedPubMedCentral Yu X, Mertz JE (1997) Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily. J Virol 71:9366–9374PubMedPubMedCentral
20.
go back to reference Zhang P, Raney AK, McLachlan A (1993) Characterization of functional Sp1 transcription factor binding sites in the hepatitis B virus nucleocapsid promoter. J Virol 67:1472–1481PubMedPubMedCentral Zhang P, Raney AK, McLachlan A (1993) Characterization of functional Sp1 transcription factor binding sites in the hepatitis B virus nucleocapsid promoter. J Virol 67:1472–1481PubMedPubMedCentral
21.
go back to reference Parekh S, Zoulim F, Ahn SH et al (2003) Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 77:6601–6612CrossRefPubMedPubMedCentral Parekh S, Zoulim F, Ahn SH et al (2003) Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 77:6601–6612CrossRefPubMedPubMedCentral
22.
go back to reference Hadziyannis SJ (2013) Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 55:183–191CrossRef Hadziyannis SJ (2013) Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 55:183–191CrossRef
23.
go back to reference Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 37:S9–S19CrossRefPubMed Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 37:S9–S19CrossRefPubMed
24.
go back to reference Hadziyannis SJ, Vassilopoulos D (2001) Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antiviral Res 52:91–98CrossRefPubMed Hadziyannis SJ, Vassilopoulos D (2001) Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antiviral Res 52:91–98CrossRefPubMed
25.
go back to reference Utama A, Siburian MD, Purwantomo S et al (2011) Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(−) patients. World J Gastroenterol 17:708–716CrossRefPubMedPubMedCentral Utama A, Siburian MD, Purwantomo S et al (2011) Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(−) patients. World J Gastroenterol 17:708–716CrossRefPubMedPubMedCentral
26.
go back to reference Rieger A, Nassal M (1995) Distinct requirements for primary sequence in the 5’- and 3’-part of a bulge in the hepatitis B virus RNA encapsidation signal revealed by a combined in vivo selection/in vitro amplification system. Nucleic Acids Res 23:3909–3915CrossRefPubMedPubMedCentral Rieger A, Nassal M (1995) Distinct requirements for primary sequence in the 5’- and 3’-part of a bulge in the hepatitis B virus RNA encapsidation signal revealed by a combined in vivo selection/in vitro amplification system. Nucleic Acids Res 23:3909–3915CrossRefPubMedPubMedCentral
27.
go back to reference Liu CJ, Cheng HR, Chen CL, Chen TC, Tseng TC, Wang ZL, Chen PJ, Liu CH, Chen DS, Kao JH (2011) Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. J Viral Hepat 18(10):e482–e490CrossRefPubMed Liu CJ, Cheng HR, Chen CL, Chen TC, Tseng TC, Wang ZL, Chen PJ, Liu CH, Chen DS, Kao JH (2011) Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. J Viral Hepat 18(10):e482–e490CrossRefPubMed
28.
go back to reference Ghabeshi S, Sharifi Z, Hosseini SM, Mahmoodian Shooshtari M (2013) Correlation between viral load of HBV in chronic hepatitis B patients and precore and Basal core promoter mutations. Hepat Mon. 13(2):7415CrossRef Ghabeshi S, Sharifi Z, Hosseini SM, Mahmoodian Shooshtari M (2013) Correlation between viral load of HBV in chronic hepatitis B patients and precore and Basal core promoter mutations. Hepat Mon. 13(2):7415CrossRef
29.
go back to reference Knaus T, Nassal M (1993) The encapsidation signal on the hepatitis B virus RNA pregenome forms a stem-loop structure that is critical for its function. Nucleic Acids Res 21:3967–3975CrossRefPubMedPubMedCentral Knaus T, Nassal M (1993) The encapsidation signal on the hepatitis B virus RNA pregenome forms a stem-loop structure that is critical for its function. Nucleic Acids Res 21:3967–3975CrossRefPubMedPubMedCentral
30.
go back to reference Junker-Niepmann M, Bartenschlager R, Schaller H (1990) A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. Embo J 9:3389–3396PubMedPubMedCentral Junker-Niepmann M, Bartenschlager R, Schaller H (1990) A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. Embo J 9:3389–3396PubMedPubMedCentral
31.
go back to reference Wynne SA, Crowther RA, Leslie AG (1999) The crystal structure of the human hepatitis B virus capsid. Mol Cell 3:771–780CrossRefPubMed Wynne SA, Crowther RA, Leslie AG (1999) The crystal structure of the human hepatitis B virus capsid. Mol Cell 3:771–780CrossRefPubMed
32.
go back to reference Hirsch RC, Lavine JE, Chang LJ et al (1990) Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 344:552–555CrossRefPubMed Hirsch RC, Lavine JE, Chang LJ et al (1990) Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 344:552–555CrossRefPubMed
33.
go back to reference Hirsch RC, Loeb DD, Pollack JR et al (1991) cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J Virol 65:3309–3316PubMedPubMedCentral Hirsch RC, Loeb DD, Pollack JR et al (1991) cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J Virol 65:3309–3316PubMedPubMedCentral
34.
go back to reference Pollack JR, Ganem D (1993) An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol 67:3254–3263PubMedPubMedCentral Pollack JR, Ganem D (1993) An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol 67:3254–3263PubMedPubMedCentral
35.
go back to reference Weber M, Bronsema V, Bartos H et al (1994) Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J Virol 68:2994–2999PubMedPubMedCentral Weber M, Bronsema V, Bartos H et al (1994) Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J Virol 68:2994–2999PubMedPubMedCentral
36.
go back to reference Zoulim F, Seeger C (1994) Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 68:6–13PubMedPubMedCentral Zoulim F, Seeger C (1994) Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 68:6–13PubMedPubMedCentral
37.
go back to reference Brunetto MR, Oliveri F, Colombatto P et al (2010) Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139:483–490CrossRefPubMed Brunetto MR, Oliveri F, Colombatto P et al (2010) Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139:483–490CrossRefPubMed
38.
go back to reference Jaroszewicz J, Calle Serrano B et al (2010) Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52:514–522CrossRefPubMed Jaroszewicz J, Calle Serrano B et al (2010) Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52:514–522CrossRefPubMed
39.
go back to reference Nguyen T, Thompson AJ, Bowden S et al (2010) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52:508–513CrossRefPubMed Nguyen T, Thompson AJ, Bowden S et al (2010) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52:508–513CrossRefPubMed
Metadata
Title
High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients
Authors
Sandrine Castelain
Véronique Descamps
Etienne Brochot
François Helle
Gilles Duverlie
Eric Nguyen-Khac
Catherine François
Publication date
01-07-2017
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 7/2017
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3312-6

Other articles of this Issue 7/2017

Archives of Virology 7/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.